Skip to content

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07358910
Acronym
RACSMEI
Enrollment
10000
Registered
2026-01-22
Start date
2025-12-18
Completion date
2027-09-30
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenovirus, Arenavirus Infections, Ascaris Lumbricoides, Brucellosis, Chikungunya, Chlamydia, Clonorchis Sinensis, Cytomegalovirus, Dengue, Diphteria, Entamoeba Histolytica, Enterovirus, Epstein Barr Virus, Giardiasis, Hantavirus Infections, Hepatitis A, Hepatitis E, Human Papilloma Virus (HPV), Influenza A and B, Japanese Encephalitis, Legionella Pneumophila Pneumonia, Leishmaniasis, Leptospirosis, Lymphatic Filariasis, Malaria, Mayaro Fever, Measles, Melioidosis, Meningitis, Mumps, Mycoplasma, Nipah Virus Infection, Norovirus Infections, Opisthorchis Viverrini, Oropouche Fever, Parvovirus, Pertussis, Q Fever, Respiratory Syncytial Virus (RSV), Rhinovirus, Rift Valley Fever, Rotavirus Disease, Rubella, Salmonella Typhi, Schistosomiasis, Severe Fever With Thrombocytopenia Syndrome, Streptococcus Pneumoniae, Strongyloides Stercoralis Infection, Tetanus, Tick-borne Encephalitis (TBE), Toxoplasma Gondii, Trichuris Trichiura, Usutu Virus Infection, Varicella, Vibrio Cholerae, West Nile Virus, Yellow Fever, Zika Virus Infection

Keywords

Infectious disease, One Health, Population-based survey, Nationally representative survey, Seroepidemiology, Multiplex serology, Seroprevalence, Vector-borne diseases, Zoonoses, Vaccine-preventable diseases, Neglected tropical diseases, Transmission dynamics, Force of infection, Mathematical modelling, Spatial epidemiology, Precision public health, Cambodia

Brief summary

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia. Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Detailed description

RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.

Interventions

None listed

Sponsors

Institut Pasteur du Cambodge
Lead SponsorOTHER
Institut Pasteur
CollaboratorINDUSTRY
CDC - Ministry of Health of Cambodia
CollaboratorUNKNOWN
UMR ASTRE (CIRAD)
CollaboratorUNKNOWN
Malaria Consortium
CollaboratorOTHER
Ministry of Agriculture, Forestry and Fisheries Cambodia
CollaboratorUNKNOWN

Study design

Observational model
FAMILY_BASED
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Residency in the village for more than 6 months; * Age between 2 and 75 years old at the time of inclusion; * For adults: provision of written consent; * For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;

Exclusion criteria

* Unable to understand or consent; * Under guardianship or deprived of liberty; * Medical conditions that impede survey participation; * Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.

Countries

Cambodia

Contacts

CONTACTClaude Flamand, Ph.D.
cflamand@pasteur-kh.org+855012333650
CONTACTNajet Hadhri, MSc.
nhadhri@pasteur-kh.org+34661400698
PRINCIPAL_INVESTIGATORClaude Flamand, Ph.D.

Institut Pasteur du Cambodge

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 26, 2026